Skip to content

clinical trail on Febrile Neutropenia in breast cancer with ongoing or after chemotherapy

An open label RCT study on the role of Pandupancanana rasa rasayana with Patoladhi kashaya anupana in Febrile Neutropenia (pandu) in QOL of CA breast cases

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045288
Enrollment
30
Registered
2022-09-07
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Sponsors

Pandith Taranath Govt Ayurvedic Medical College and Hospital Bellary
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects diagnosed with breast cancer and having signs and symptoms of febrile neutropenia. 2. Patients of either sex aged between 20-70 years who have refused for chemotherapy and radio therapy and who have dropped from chemotherapy and radio therapy due to febrile neutropenia 3. Patients fit for oral administration of drugs. 4. Patients who have signed the informed consent form. 5. Patients developing febrile neutropenia with ANC- 500- 1500cells/mcl 6. Patients with HB% above 6 gms%-11gm% 7. Patients with WBC count above 2000 cells/ mcl 8. Patients with RBC count above 2 million cells/ mcl 9. Patients with platelet count above 50,000cells/ mcl 10. Patients with temperature above 1000F and below 1050F.

Exclusion criteria

Exclusion criteria: 1. Patients who are unconscious, or in stage of coma, MODS. 2. Patients with Oncological emergencies, leukemia, bleeding tumors etc. 3. Absolute neutrophil count 4. Patients who have not signed informed consent form.

Design outcomes

Primary

MeasureTime frame
1) Increase nuetrophill count 2) Bring down fever ( body temperature) 3) Relief from symptomsTimepoint: 55 Days

Secondary

MeasureTime frame
Increase the quality of life and continue the all chemotherapy cycles without any dropoutsTimepoint: 55 DAYS

Countries

India

Contacts

Public ContactDr Hemanthkumar P

TGAMC and hospital Bellary

drmvdbly@gmail.com9844094290

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026